Zuclopenthixol Short-Acting Intramuscular Injection Suppliers & Bulk Manufacturers
Available Forms: Short-acting Intramuscular Injection
Available Strengths: 50 mg/mL
Reference Brands: Clopixol-Acuphase®
Category:
Antipsychotropic Drugs
Zuclopenthixol short-acting IM injection is a typical antipsychotic that works by blocking dopamine D2 receptors, helping to rapidly reduce symptoms of acute psychosis and agitation. It is primarily used in emergency settings to calm aggressive or severely disturbed patients with schizophrenia or related psychotic disorders, offering quick symptom control
Zuclopenthixol Short-acting Intramuscular Injection is available in Short-acting Intramuscular Injection
and strengths such as 50 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Zuclopenthixol Short-acting Intramuscular Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Zuclopenthixol Short-acting Intramuscular Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Zuclopenthixol short-acting intramuscular injection, commonly used in acute psychosis and agitation, is not currently approved by the FDA in the United States but is available in several EU markets under Clopixol-Acuphase. In the EU, it follows EMA regulatory standards for parenteral antipsychotics, requiring GMP compliance, stability data, and clinical justification for emergency psychiatric use. U.S. registration would require a detailed regulatory strategy, including an IND or 505(b)(2) approach. To explore other dosage forms, strengths, and dossier-ready Zuclopenthixol IM injection products, visit Pharmatradz.com — your trusted global B2B platform for API and finished formulations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing